Literature DB >> 8069968

(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects.

K Nishimura1, Y Hashimoto, S Iwasaki.   

Abstract

The rate of racemization of N(alpha)-phthalimidoglutarimide (thalidomide) was determined as its half life to be 566 min at pH 7.4/37 degrees C. This fast racemization of thalidomide resulted in no apparent difference between (S)- and (R)-forms of the compound on enhancing activity of phorbol ester-induced tumor necrosis factor (TNF)-alpha production by human leukemia HL-60 cells. Optically pure forms of structurally related analog of thalidomide, (S)- and (R)-alpha-methyl-N(alpha)-phthalimidoglutarimides (methylthalidomides), which do not racemize under the physiological condition, were prepared. Only (S)-form of methylthalidomide, but not its (R)-form, elicited TNF-alpha production-enhancing effect, suggesting that the (S)-isomer of thalidomide would be the active form in terms of thalidomidal biological response modifying effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8069968     DOI: 10.1248/cpb.42.1157

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  10 in total

Review 1.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

2.  Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.

Authors:  Vincent Jacques; Anthony W Czarnik; Thomas M Judge; Lex H T Van der Ploeg; Sheila H DeWitt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

Review 3.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

4.  Crystal structure of (S)-4-carbamoyl-4-(1,3-dioxo-isoindolin-2-yl)butanoic acid.

Authors:  Kohei Otogawa; Kazuhiko Ishikawa; Motoo Shiro; Toru Asahi
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-01-01

5.  Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications.

Authors:  Mayaka Maeno; Etsuko Tokunaga; Takeshi Yamamoto; Toshiya Suzuki; Yoshiyuki Ogino; Emi Ito; Motoo Shiro; Toru Asahi; Norio Shibata
Journal:  Chem Sci       Date:  2014-10-30       Impact factor: 9.825

6.  Structural basis of thalidomide enantiomer binding to cereblon.

Authors:  Tomoyuki Mori; Takumi Ito; Shujie Liu; Hideki Ando; Satoshi Sakamoto; Yuki Yamaguchi; Etsuko Tokunaga; Norio Shibata; Hiroshi Handa; Toshio Hakoshima
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

7.  Crystal structure of the thalidomide analog (3aR*,7aS*)-2-(2,6-dioxopiperidin-3-yl)hexa-hydro-1H-iso-indole-1,3(2H)-dione.

Authors:  Yousef Hijji; Ellis Benjamin; Jerry P Jasinski; Ray J Butcher
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-10-16

8.  Molecular mechanisms of thalidomide and its derivatives.

Authors:  Takumi Ito; Hiroshi Handa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2020       Impact factor: 3.493

9.  Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers.

Authors:  Etsuko Tokunaga; Takeshi Yamamoto; Emi Ito; Norio Shibata
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

Review 10.  Molecular Mechanisms of the Teratogenic Effects of Thalidomide.

Authors:  Tomoko Asatsuma-Okumura; Takumi Ito; Hiroshi Handa
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.